EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE Drug Patent Profile

Which patents cover Emtricitabine And Tenofovir Alafenamide Fumarate, and when can generic versions of Emtricitabine And Tenofovir Alafenamide Fumarate launch?

Emtricitabine And Tenofovir Alafenamide Fumarate is a drug marketed by Apotex and Lupin Ltd and is included in two NDAs.

The generic ingredient in EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Alafenamide Fumarate

A generic version of EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE was approved as emtricitabine; tenofovir alafenamide fumarate by LUPIN LTD on December 13^th, 2024.

Summary for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

US Patents:	0
Applicants:	2
NDAs:	2
Clinical Trials:	45
DailyMed Link:	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE at DailyMed

Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jos Antonio Mata Marn	PHASE3
Instituto Mexicano del Seguro Social	PHASE3
Shanghai Public Health Clinical Center	NA

See all EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE clinical trials

US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	214053-001	May 17, 2024		DISCN	No	No
Apotex	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	214053-002	May 17, 2024		DISCN	No	No
Lupin Ltd	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	213926-001	Dec 13, 2024	AB	RX	No	No

Market Dynamics and Financial Trajectory for Emtricitabine and Tenofovir Alafenamide Fumarate

Last updated: February 20, 2026

What are the current market fundamentals for emtricitabine and tenofovir alafenamide fumarate (TAF)?

Emtricitabine (FTC) combined with tenofovir alafenamide (TAF) is a core component of antiretroviral therapy (ART) for HIV. TAF is a prodrug of tenofovir with a better safety profile than tenofovir disoproxil fumarate (TDF). The combination, marketed notably as Genvoya (by Gilead Sciences) and Descovy (by Gilead), has gained popularity due to superior renal and bone safety profiles.

The HIV therapy market generated approximately $20 billion in global revenue in 2022. Gilead and its competitors, including ViiV Healthcare and Merck & Co., dominate this segment. Gilead's revenues from TAF-based products surpassed $8 billion in 2022, driven by increased adoption in developed markets.

How has the market evolved over the past five years?

Transition from TDF to TAF formulations accelerated post-2016. Gilead launched Descovy in 2016 and Genvoya in 2017, which contributed significantly to sales growth.

Key milestones include:

• 2016: Introduction of TAF-based products; rapid uptake in North America and Europe.
• 2018-2020: Market share for TAF formulations increased to over 70% in HIV-preventive and treatment segments.
• 2021-2022: Expansion into pediatric populations and more countries, driven by patent protections and approvals.

Market penetration is favored in high-income settings due to better tolerability and fewer side effects. Emerging markets rely more heavily on generic TDF formulations, but TAF's safety benefits position it for gradual growth.

What are the key competitive and regulatory factors?

Gilead's patent protection for TAF-based formulations extends roughly until 2028 in Western jurisdictions. Patent litigations and biosimilar competition may influence pricing and market volume beyond that point.

ViiV Healthcare's Dolutegravir-based regimens compete directly, affecting TAF market share. Regulatory approvals for TAF in pre-exposure prophylaxis (PrEP) and pediatric indications bolster growth potential.

The global push for increased HIV diagnosis and treatment, aiming for 90-90-90 targets, fuels demand for effective therapies like TAF-based regimens.

What is the financial trajectory forecast?

Market analysts project sustained growth in TAF-based product sales, with compounded annual growth rates (CAGRs) between 5% and 8% for 2023-2028.

Year	Estimated Global Revenue (USD Billion)	Growth Rate (%)
2023	10.4	6.5
2024	11.1	6.7
2025	12.0	8.1
2026	13.0	8.3
2027	14.0	7.7
2028	15.1	7.9

Factors supporting this include:

• Increased adoption in developed countries.
• Expansion into pediatric and prophylactic markets.
• Continued patent protections and regulatory approvals.

Potential headwinds involve generic competition post-2028, pricing regulations, and patent challenges that could reduce margins.

What are the risks and opportunities?

Opportunities:

• Growth in HIV treatment and prevention globally.
• Development of next-generation formulations with improved tolerability.
• Expansion into other viral diseases, leveraging proprietary platforms.

Risks:

• Patent expiry leading to generic erosion.
• Competitive pressure from new drugs, such as cabotegravir-based injectables.
• Price regulation and reimbursement policies, especially in low- and middle-income countries.

Closing summary

Emtricitabine combined with tenofovir alafenamide exhibits strong growth prospects driven by safety advantages over TDF and expanding global HIV treatment initiatives. Gilead maintains a dominant position, with revenues forecasted to grow at a mid-single-digit CAGR until patent expiry, after which generic competition could significantly impact financial outcomes.

Key Takeaways

• TAF’s superior safety profile has led to increased market share in HIV therapy.
• Revenue from TAF-based regimens is expected to grow to over $15 billion by 2028.
• Patent protections via 2028 restrict generic competition; post-expiry, rapid erosion is likely.
• Competition from alternative therapies and regulatory changes present ongoing risks.
• Expansion into preventative and pediatric markets offers additional opportunities.

FAQs

1. When do patent protections for Gilead’s TAF formulations expire?
Patents are expected to last until 2028 in key markets, after which generics could enter the market.

2. How does TAF compare with other antiretroviral drugs?
TAF offers a better safety profile concerning renal and bone health compared to TDF and has fewer side effects, making it favorable for long-term management.

3. What markets hold the highest growth potential for TAF-based drugs?
Developed markets in North America and Europe currently dominate, but emerging markets present long-term growth due to the global HIV burden.

4. Who are the primary competitors?
ViiV Healthcare’s Dolutegravir-based regimens, Merck’s integrase inhibitors, and upcoming generic manufacturers pose competitive challenges.

5. What regulatory developments could influence market trajectory?
Approvals for new indications (e.g., PrEP, pediatric use) and generics’ patent challenges are critical regulatory factors affecting growth and revenue.

References

1. Gilead Sciences. (2022). Annual Report.
2. IQVIA. (2022). HIV Market Analysis Reports.
3. World Health Organization. (2022). HIV/AIDS Country Data.
4. U.S. Patent and Trademark Office (USPTO). Patent expiration dates.
5. Evaluate Pharma. (2023). 2023 Global HIV Therapy Market Forecasts.

[1] Gilead Sciences. (2022). Annual Report.
[2] IQVIA. (2022). HIV Market Analysis Reports.
[3] World Health Organization. (2022). HIV/AIDS Country Data.
[4] U.S. Patent and Trademark Office. Patent expiry info.
[5] Evaluate Pharma. (2023). Global HIV Therapy Market Forecasts.